NAD+ injection side effects: what’s known and what isn’t

NAD+ injections are usually described as low-risk, and the reactions clinics list are mostly mild. The honest answer, though, is that nobody has measured how often side effects happen. NAD+ has no FDA label, and no controlled trial has tested subcutaneous NAD+ injections in people. What we know comes from clinics’ own safety notes, two small IV studies and trials of oral NAD+ precursors.

This guide sets out what each source shows and what to check before you start.

Side effects clinics list for NAD+ injections

Online clinics that prescribe NAD+ injections publish similar lists. These are the side effects on their pages, read on October 18, 2026:

None of these lists comes with a rate, because the data to calculate one doesn’t exist. They are the reactions clinics’ clinicians and patients report, not trial results. Luvo Health’s advice about allergic reactions is worth noting: trouble breathing, facial swelling or trouble swallowing after a dose needs urgent care. Hone Health also says NAD+ should not be used during pregnancy or breastfeeding, and that people with active cancer should have it cleared by their oncologist first.

Injection technique matters for the most common problem. Luvo Health tells patients to rotate sites among the abdomen, thigh and upper arm, and to avoid irritated skin. AgelessRx suggests changing placement on the body, or injecting less often, if irritation develops.

What the IV studies show

Two small studies give the only published human data on NAD+ given directly into the body, and both used IV drips rather than the shots most online clinics sell.

In a 2019 pilot, 8 men aged 30 to 55 received 750 mg of NAD+ over 6 hours, about 2 mg a minute, and 3 received saline. The researchers saw no adverse events in either group. A small rise in bilirubin, which they thought might come from the infusion breaking down some red cells, wasn’t clinically relevant.

A 2026 retrospective review of one commercial clinic’s records tells a different story at a faster pace. Six people received 500 mg of NAD+ by IV on four days in a row. All six reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, a faster heart rate, throat pain, congestion or chest pressure during the drips. Infusions took 97 minutes on average because staff slowed them, against 37 minutes for the comparison group given nicotinamide riboside. Every symptom resolved when the infusion ended, and liver, kidney, thyroid and inflammation markers didn’t change over 30 days, though HDL (“good”) cholesterol fell in the NAD+ group.

The comparison group is informative too. Of 8 people given IV nicotinamide riboside, an NAD+ precursor, 5 reported only minor tingling in the tongue, jaw or arms and mild cramping, and one paused for severe cramping that coincided with menstruation. HbA1c, a long-term blood sugar marker, fell in that group. The difference suggests the symptoms come from NAD+ itself arriving quickly, not from the drip.

Together, the two studies suggest that how fast NAD+ goes in drives how people feel. They don’t tell us what a daily subcutaneous shot does, and with 14 people between them they can’t rule out rare problems.

What oral precursor trials add

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are taken by mouth and converted into NAD+ in the body. In a 6-week randomized crossover trial in healthy middle-aged and older adults, NR was well tolerated while it raised NAD+ metabolism. That is reassuring about raising NAD+ itself over weeks. It isn’t evidence about injected NAD+, which skips the gut and liver and arrives in different amounts.

What isn’t known

• Long-term safety. No study has followed people on NAD+ injections, drips or sprays for months or years.
• Rates. Without a controlled trial, there is no way to say how often any side effect happens, or whether it is caused by NAD+ rather than by chance.
• Interactions. Without an FDA label, there is no official list of medicines or conditions that don’t mix with NAD+.
• Groups not studied. The studies above enrolled healthy adults. We found no published data in pregnancy, in children, or in people with serious illness.

Compounding quality is a safety question too

Every NAD+ product sold online is compounded, because there is no FDA-approved NAD+ drug. Compounded medicines aren’t reviewed by the FDA for safety, effectiveness or quality before they reach you (FDA).

NAD is in Category 1 of the FDA’s 503A bulk substances list, updated May 14, 2026. Under the FDA’s interim policy, a licensed 503A pharmacy may compound it for an individual prescription if the ingredient comes from an FDA-registered manufacturer with a valid certificate of analysis. One salt form, beta-NAD disodium salt trihydrate, is in Category 3 and isn’t covered.

Questions worth asking before you start:

• Which pharmacy will fill the prescription, and is it licensed in your state? PepScribe publishes its three pharmacies with their NPI numbers.
• Is the product stability-tested, and how should it be stored? Many injectables need refrigeration.
• Who do you contact about a reaction, and how fast do they answer?

Storage, handling and nasal spray

How a compounded injectable is stored affects what you inject. Luvo Health tells patients to store medication exactly as the label says, notes that many injectables need refrigeration, and says not to freeze them unless instructed. PepScribe says some of its injectables, including NAD+, are stability-tested for a longer shelf life. Ask your pharmacy for the beyond-use date and don’t use a vial past it.

NAD+ nasal spray avoids injection-site reactions, but we found no published safety study of it at all, and clinics don’t list separate side effects for the spray. If you switch from injections to the spray, the dose and how much reaches your blood are both likely to change, so treat it as a new product and ask your prescriber how to dose it.

Practical steps if you use NAD+ injections

• Give your prescriber your full medical history and every medicine and supplement you take.
• Use the dose and schedule on your label. If you’re unsure, ask before taking an extra dose.
• Rotate injection sites and follow the storage instructions.
• Stop and get urgent care for signs of an allergic reaction.
• Report a side effect to your prescriber and to the FDA’s MedWatch program (1-800-FDA-1088).

How the risk compares with the benefit

A side-effect profile only makes sense next to the benefit. For NAD+ injections, the benefit side is unproven: no trial has shown that they improve energy, slow aging or extend life. We cover that evidence in NAD+ therapy: what the evidence shows, and the full drug facts on our NAD+ treatment page.

As of October 2026, NAD+ injections cost $99 to $224 a month at the 5 online clinics that publish a monthly price, with any required membership included; see the NAD+ provider rankings and the longevity hub for each clinic’s terms.

The bottom line

The reactions clinics report for NAD+ injections are mostly mild and local, and the one slow IV study saw none. Fast IV drips caused moderate to severe symptoms in everyone who had them. Beyond that, the safety record is blank: no label, no controlled trial and no long-term data. If you decide to try it, choose a licensed clinician and a named pharmacy, follow the dose you’re given, and treat any new symptom as worth reporting.